CJC-1295: Natty or Not? | Still Natty Abstract gradient background for Still Natty peptides guide
Still Natty
Back to Peptides

CJC-1295

Natty
growth hormoneGHRHsubcutaneous

What It Does

Increases growth hormone and IGF-1 for 6+ days per injection. Improves body composition, muscle recovery, and fat metabolism. Weekly dosing.

Natty Status Classification

This peptide is generally considered within the natty realm by some in the fitness community, particularly when used for therapeutic healing purposes. However, opinions vary, and competitive natural bodybuilding organizations may have different stances. Always check your federation's specific rules if you compete.

Description

GHRH analog with extended half-life (6-8 days with DAC). 2-10x GH increase for 6+ days. Synergistic with Ipamorelin (3-5x boost via dual receptor targeting). Phase 2 trials discontinued after death. Cardiovascular risks. Not FDA-approved.

Full Description

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) and growth hormone secretagogue developed by ConjuChem Biotechnologies.

Two distinct forms exist: CJC-1295 WITH DAC (Drug Affinity Complex) features covalent albumin binding extending half-life to 5.8-8.1 days, while CJC-1295 WITHOUT DAC (Modified GRF 1-29) has 30-minute to 2-hour half-life requiring multiple daily doses.

WITH DAC version binds to GHRH receptors in pituitary, activating G-proteins and increasing cAMP/IP3 production, resulting in 2-10 fold GH increases for 6+ days and 1.5-3 fold IGF-1 increases for 9-11 days after single injection.

After multiple doses, IGF-1 remains elevated for 28 days.

Phase 2 clinical trials for HIV-associated lipodystrophy and growth hormone deficiency showed sustained, dose-dependent GH/IGF-1 increases with good tolerability at 30-60 mcg/kg doses.

Synergistic effects with Ipamorelin: Research indicates combining CJC-1295 with Ipamorelin produces enhanced GH release compared to either peptide alone.

CJC-1295 (GHRH analog) and Ipamorelin (selective GHRP mimicking ghrelin) target different receptor families in the pituitary, creating complementary stimulation—CJC-1295 provides sustained GH release while Ipamorelin induces rapid GH spikes.

Similar peptide combinations (GHRH analog + GHRP-2) showed synergistic interaction: individual compounds produced 20-fold and 47-fold GH increases respectively, but simultaneous application achieved 54-fold increase.

Clinical practitioners report the combination typically produces 3-5 fold increase in GH release versus monotherapy, though this specific claim for CJC-1295/Ipamorelin lacks published human trial verification.

The dual-action mechanism may enhance muscle mass, fat metabolism, recovery, and sleep quality.

Development discontinued following patient death during trials (attributed to unrelated coronary artery disease), though research terminated as precaution.

Critical safety concerns include cardiovascular risks: FDA warns of increased heart rate, systemic vasodilation, flushing, transient hypotension.

Elevated GH/IGF-1 can cause cardiac hypertrophy, fluid retention, increased blood pressure, particularly dangerous for pre-existing cardiovascular conditions.

Not FDA-approved; classified as Investigational New Drug available only for research.

Removed from FDA Category 2 list September 2024, making it eligible for Pharmacy Compounding Advisory Committee review.

Banned by WADA for competitive sports.

DAC version typically dosed 1-2x weekly, non-DAC version requires daily or twice-daily dosing.

What is Lyophilized Powder?

Lyophilized powder is a sterile, freeze-dried medication that must be reconstituted (mixed with a liquid solvent, like sterile water) before it can be injected. This process extends the drug's shelf life and stability, making it ideal for temperature-sensitive products. The lyophilization process removes water from the peptide in a frozen state through sublimation, which preserves the physical and chemical properties until it is needed.

Application Methods

  • Subcutaneous injection

Product Names

  • CJC-1295 with DAC
  • CJC-1295 without DAC
  • Modified GRF 1-29

Benefits

  • 2-10 fold increase in GH for 6+ days (single dose with DAC)
  • 1.5-3 fold IGF-1 increase sustained 9-11 days
  • IGF-1 remains elevated 28 days after multiple doses
  • Extended half-life (5.8-8.1 days with DAC) allows weekly dosing
  • Safe and well-tolerated at 30-60 mcg/kg in clinical trials
  • Normalized growth parameters in animal models with daily dosing
  • Preserved pulsatile GH secretion patterns vs exogenous GH
  • Proteomic changes suggesting metabolic improvements
  • Potential body composition improvements
  • Subcutaneous administration

Dosage Levels

  • CJC-1295 WITH DAC: 30-60 mcg/kg once or twice weekly (clinical trial dose)
  • CJC-1295 WITH DAC: 1-2mg per week (typical subcutaneous dose)
  • CJC-1295 WITHOUT DAC (Modified GRF 1-29): 100-200mcg 1-3x daily
  • WITHOUT DAC: Requires daily or twice-daily dosing due to 30min-2hr half-life
  • WITH DAC: Weekly dosing sufficient due to 6-8 day half-life
  • Stack with GHRP peptides (e.g., Ipamorelin) for synergistic effects
  • Cardiovascular screening required before use
  • Not recommended for those with pre-existing heart conditions

Research

Where to Buy

*Peptides are stored in form and need to be reconstituted with sterile bacteriostatic water before use.

Related Peptides

CJC-1295/Ipamorelin Stack

Natty

Boosts growth hormone 3-5x higher than individual peptides. Improves sleep quality, muscle mass, fat loss, and recovery. Minimal side effects.

IGF-1 LR3

Natty

Powerfully increases muscle growth, protein synthesis, and fat burning. Accelerates tissue repair and recovery. Risk of hypoglycemia.

Ipamorelin

Natty

Stimulates growth hormone release without cortisol/prolactin effects. Improves sleep quality, recovery, and body composition. Minimal side effects.
Last Updated: 10/19/2025